In addition, Ohki et al. reported that SGLT2 inhibitor was effective for patients with NAFLD refractory to incretin-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors. This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.